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Abstract 
Background: Although compounding has a long-standing tradition in clinical practice, insurers and pharmacy 
benefit managers have instituted policies to decrease claims for compounded medications, citing questions 
about their safety, efficacy, high costs, and lack of Food and Drug Administration (FDA) approval. There are no 
reliable published data on the extent of compounding by community pharmacists nor the fraction of patients 
who use compounded medications. Prior research suggests that compounded medications represent a relatively 
small proportion of prescription medications, but these surveys were limited by small sample sizes, subjective 
data collection methods, and low response rates.  
 
Objective: To determine the number of claims for compounded medications, on a per user per year (PUPY) 
basis, and the average ingredient cost of these claims among commercially insured patients in the United States 
(US) for 2012 and 2013. 
 
Methods: This study used prescription claims data from a nationally representative sample of commercially 
insured members whose pharmacy benefits were managed by a large pharmacy benefit management company. 
A retrospective claims analysis was conducted from January 1, 2012 through December 31, 2013. Annualized 
prevalence, cost, and utilization estimates were drawn from the data. All prescription claims were adjusted to 
30-day equivalents. Data mining techniques (association rule mining) were employed in order to identify the 
most commonly combined ingredients in compounded medications. 
 
Results: The prevalence of compound users was 1.1% (245,285) of eligible members in 2012 and 1.4% 
(323,501) in 2013, an increase of 27.3%. Approximately 66% of compound users were female and the average 
age of a compound user was approximately 42 years throughout the study period. The geographic distribution 
of compound user prevalence was consistent across the US. Compound users’ prescription claims increased 
36.6%, from approximately 7.1 million to approximately 9.7 million prescriptions from 2012 to 2013. The 
number of claims for compounded medications increased by 34.2% from 486,886 to 653,360 during the same 
period. PUPY utilization remained unchanged at 2 prescriptions per year from 2012 to 2013. The most 
commonly compounded drugs were similar for all adult age groups, and represented therapies typically 
indicated for chronic pain or hormone replacement therapy. The average ingredient cost for compounded 
medications increased by 130.3% from $308.49 to $710.36 from 2012 to 2013. The average ingredient cost for 
these users’ non-compounded prescriptions increased only 7.7%, from $148.75 to $160.20. For comparison, the 
average ingredient cost for all prescription users’ claims was $81.50 in 2012, and increased by 3.8% to $84.57 
in 2013. 
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Conclusions: Compound users represented 1.4% of eligible members in 2013. The average ingredient cost for 
compound users’ compounded prescriptions ($710.36) was greater than for non-compounded prescriptions 
($160.20). The one-year increase in average compounded prescription costs (130.3%) was also greater than for 
non-compounded prescriptions (7.7%). Although prevalence of compound users and the PUPY utilization for 
compounded prescriptions increased only slightly between 2012 and 2013, the mean and median cost of 
compounded medications increased dramatically during this time. Text mining revealed that drug combinations 
characteristic of topical pain formulations were among the most frequently compounded medications for adults. 
  
What is already known about this subject: 
o Scrutiny of compounded medications by insurers and regulatory agencies has recently increased. There 
are no published objective data on the number of compounded medications dispensed by community 
pharmacists nor the costs associated with these prescriptions. 
o Prior studies on the extent of compounding were based on surveys with small numbers of responses and 
respondents’ self-reported data. 
What this study adds: 
o This is the first published study to profile trends in use and cost of compounded medications using an 
objective, nationally representative dataset. 
o It is the first study to apply associative data mining procedures to discern the most often compounded 
drugs and the conditional likelihood to observe the occurrence of Drug B if Drug A were present.  
 
Disclosures 
Southern Illinois University Edwardsville School of Pharmacy and St. Louis College of Pharmacy are members 
of Professional Compounding Centers of America (PCCA). No proprietary or confidential information 
regarding PCCA was consulted in conducting and reporting this research. 
The authors report no financial or other conflicts of interest. 
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Utilization and costs of compounded medications for commercially insured patients, 2012 – 2013. 
Introduction 
Community pharmacists have traditionally compounded medications to provide patients with alternative 
doses or combinations of drugs, allergen-free formulations, or dosage forms that were not commercially 
available1. Pharmacy compounding allows for “…the preparation, mixing, assembling, altering, packaging, and 
labeling of a drug, drug-delivery device, or device in accordance with a licensed practitioner’s prescription, 
medication order, or initiative based on the practitioner/patient/pharmacist/compounder relationship in the 
course of professional practice.”2 
Although compounding has a long-standing tradition in clinical practice, insurers and pharmacy benefit 
managers have recently instituted policies to decrease claims for compounded medications, citing questions 
about their safety, efficacy, high costs and lack of Food and Drug Administration (FDA) approval.3-5 A 
heightened focus has been placed on the practice of compounding by citizens, regulators, and insurers since the 
2013 tragedy of contaminated steroid injections from New England Compounding Center, which caused serious 
infections and other injuries to at least 751 patients and resulted in at least 64 patient deaths.6-8 The use of 
compounded oral, topical, and transdermal medications dispensed by community pharmacies is also 
increasingly being scrutinized.9 Proponents of compounding have argued that compounded medications 
represent invaluable personalized therapies for patients who are not treated adequately with traditional FDA-
approved drug products.10, 11  
Amidst this debate, two important questions remain unanswered: how many patients use compounded 
medications per year, and how much do the medications cost? Survey research suggests that compounded 
medications represent a relatively small portion of prescription medications, ranging from 2.3% to 12.2%.12-15 
However, these studies were limited by small sample sizes, subjective data collection methods, and low 
response rates. As such, there are no reliable published data on the extent of compounding by community 
pharmacists nor the fraction of patients who use compounded medications.  
Considering that 61.8% of the United States (US) population have private health insurance coverage and the 
Affordable Care Act requires prescription drug coverage as one of the ten essential benefits that health plans 
must provide, prescription claims data can be leveraged to examine prevalence, cost and utilization trends 
among compounded medications.16, 17 With limited information about the usage patterns of compounded 
medications, prescription claim databases offer the advantages of objective data, sample sizes that are 
representative of a large proportion of the US population, and detailed information on compounded medications. 
The objective of this study was to determine the number of claims for compounded medications, on a per user 
per year (PUPY) basis, and the average ingredient cost of these claims among commercially insured patients in 
5 
 
the United States for 2012 and 2013. An additional goal was to examine which drugs were most often 
compounded together. 
 
Methods 
Population 
This study used prescription claims data from a nationally representative sample of commercially insured 
members whose pharmacy benefits were managed by a large pharmacy benefit management company. The 
health plan sponsors for these benefits included private- and public-sector employer groups, managed care 
organizations, third-party administrators, and unions. Inclusion was limited to members who were eligible for 
pharmacy benefits at any time between January 1, 2012 and December 31, 2013.  
Study Design 
A retrospective claims analysis was conducted from January 1, 2012 through December 31, 2013. 
Annualized prevalence, cost and utilization estimates were drawn from the data. All prescription claims were 
adjusted to 30-day equivalents by dividing the days supply by 30.4. This normalization is based on an average 
month, calculated as 365 days/year ÷ 12 months/year = 30.4 days per month.  
Under provisions of the Health Insurance Portability and Accountability Act of 1996, all data specific to 
individual patients were removed from internal analytical datasets to maintain the privacy of protected health 
information. The study was declared exempt by both Southern Illinois University Edwardsville (SIUE) and St. 
Louis College of Pharmacy Institutional Review Boards, as only de-identified administrative pharmacy claims 
data were used.  
Study Variables 
The primary outcome measures were number and percent of compound utilizers by age bands, prevalence of 
users, PUPY utilization and cost associated with compounded medication. Members were defined as persons 
eligible for prescription benefits at any time between January 1, 2012 and December 31, 2013. Prescription 
medication users were defined as members who had at least one claim for a prescription medication between 
January 1, 2012 and December 31, 2013. Compound users were defined as those prescription medication users 
who had at least one claim for a compounded medication during the same period. Compounded medications 
were identified at the point of service by the medication provider and submitted to the pharmacy benefit 
manager. Age categories were birth to nine years, 10 to 19 years, 20 to 29 years, 30 to 39 years, 40 to 49 years, 
50 to 59 years, 60 to 69 years, and 70 years or older. Prevalence of compound users was calculated as the 
number of patients with at least one compound prescription in a calendar year divided by the number of 
members eligible for pharmacy benefits for that year, expressed as a percentage. Utilization measures were 
based on prescription claim counts. PUPY utilization for compounded medications was calculated as the 
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number of 30-day adjusted compounded prescriptions divided by the number of compound medication utilizers 
per year. Average cost per prescription was calculated by dividing the total ingredient cost of compounded 
medication claims by the number of 30-day adjusted compounded medication prescriptions per year. Ingredient 
cost was calculated according to the average wholesale price (AWP), without administrative or dispensing fees.   
Analysis 
Descriptive and bivariate statistics were generated for the prevalence of use, cost and utilization measures 
for 2012 and 2013. Prevalence of compound users was analyzed by age groups and gender as well as by 
geography. Most often utilized drugs were also analyzed by age group to detect similarities/differences in the 
type of compounded drugs used by patients in different age-bands and gender.  
In order to identify the most commonly combined ingredients in compounded medications, the data mining 
technique of association rule was employed. Data mining is increasingly being used in healthcare research to 
examine a myriad of issues, including hospital infection control, screening adverse drug reactions, predicting 
heart disease, exposure to air pollution and respiratory illness, diagnosing medical conditions, and in clinical 
observations.18-23 However, to our knowledge, this is the first study to apply associative rule mining to analyze 
compounded medications.  
A priori algorithms for mining association rules were used in this study to identify drugs that were most 
often compounded together. An a priori algorithm uses an iterative approach where n item sets are used to 
explore n+1 item sets. In this study, item sets refer to unique drugs or different combinations of drugs. This 
approach efficiently ascertains frequent sets in data.  
To address the possibility of many frequently occurring combinations of drugs, minimum levels of support 
(frequency) and confidence (conditional probability) were used. Support refers to how many times a particular 
item/item set appears in the data and confidence refers to the conditional probability of item y appearing when 
item/item set x is observed. In this study, we used a minimum support of 10% to determine how often a 
particular drug or a combination of drugs appeared in compound medication claims. In addition, a minimum 
confidence threshold of 50% was used to determine the drug combinations that occurred when a particular drug 
(with at least 10% support) was observed in compound medication claims. 
Results 
Claims from retail pharmacies constituted more than 99% of total claims for compounded medications. The 
remaining claims originated from hospitals, mail-order pharmacies, or other non-retail pharmacies.  
Compound users 
The demographics of the study population are summarized in Table 1. The number of eligible members in 
2012 and 2013 were 22,314,101 and 22,745,508, respectively. Approximately two-thirds of members used at 
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least one prescription medication in both 2012 and 2013. The average age of prescription user was 36.9 in 2012 
and 36.8 in 2013. Females represented 51.6% of prescription medication users in 2012 and 51.5% in 2013. 
Compound users represented 1.1% of members (245,285) in 2012 and 1.4% of members (323,501) in 2013. 
Compound users increased by 78,216 from 2012 to 2013, while members increased by 431,407. The prevalence 
of compound users thus increased by 27.3% while the number of members increased by 1.9%. The prevalence 
of prescription medication users increased by only 1% during this time. 
The distribution of compound users by age and gender is shown in Figure 1. The distributions were similar 
for 2012 (Figure 1A) and 2013 (Figure 1B). Overall, the average age of a compound user was approximately 42 
years, and approximately two thirds of compound users were female. Patients under 10 years old represented 
the only category with a greater number of male than female compound users. The greatest proportion of female 
compound users were aged 50 – 59 (approximately 26%) followed by 40 – 49 (approximately 18%), and 30 – 
39 and 60 – 69 (approximately 14% each). The age distribution for male compound users was bimodal, with the 
greatest proportion of 50 – 59 year olds (approximately 19%) and children under 10 years (approximately 18%). 
The smallest proportion of compound users were aged 10 – 19 and greater than 70 years (approximately 6% 
each) for females and 20 – 29 and greater than 70 years (approximately 7% each) for males.  
The prevalence of compound users by state of residence for 2013 is shown in Figure 2A. The national 
average for prevalence of compound users was 1.4% and 40 states exhibited compound user rates of 1 – 2%. 
Oklahoma (3.5%), Tennessee (2.4%), Alabama (2.3%), and Texas (2.2%) were the only states with prevalence 
greater than 2%. The percentage increase in compound user prevalence from 2012 to 2013 is shown in Figure 
2B. North Dakota was the only state with a decrease in the rate of compound users (–8.3%), while Iowa, 
Massachusetts, Michigan, and New Hampshire exhibited no change. The largest increase in compound users 
occurred in Texas (69.2%), Arkansas (62.5%), Mississippi (54.5%), Connecticut (50%), Hawaii (50%), New 
Jersey (50%), and Florida (45.5%). All other states exhibited an increase in prevalence of 7 to 37.5%.  
Claims for compounded medications 
Compound users’ prescription cost and utilization data are summarized in Table 2. There were nearly 7.1 
million prescription claims for compound users in 2012, of which 486,886 (6.9%) were compounded. In 2013, 
claims increased to nearly 9.7 million total prescriptions (36.6% increase) and 653,360 compounded 
medications (34.2% increase). The average utilization was 2 compounded prescriptions PUPY in both 2012 and 
2013. 
Prescription ingredient costs 
Ingredient cost statistics for compound users’ prescription claims are shown in Table 2 and Figure 3. Both 
the mean and median costs were greater for compounded medications than non-compounded drugs. The 
average cost was $308.49 for compounded prescriptions and $148.75 for non-compounded prescriptions in 
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2012. In 2013, the average cost of compounded prescriptions increased by 130.3% to $710.36, while non-
compounded prescription increased by 7.7% to $160.20. For comparison, the average ingredient cost for all 
prescription users’ claims was $81.50 in 2012 and increased by 3.8% to $84.57 in 2013. The median costs for 
both types of prescriptions were much lower than the average values, reflecting the influence of a small number 
of very high cost claims on the cost distribution (Figure 3). The median cost for compounded medications 
increased by 54.9% from $61.00 to $94.49, while non-compounded prescriptions decreased 17.7% from $29.63 
to $24.39.  
Ingredients in compounded medications 
The ten drugs most frequently included in compounded prescriptions in 2013 are shown in Table 3. Inactive 
ingredients (diluents, ointment bases, flavorings, etc.) were not included in this analysis, but they were included 
in the cost analysis (reported next). The lists for all adult age groups (≥ 20 years) were similar for both 2012 
(data not shown) and 2013. These drugs primarily represent therapies for pain management (gabapentin, 
baclofen, cyclobenzaprine, diclofenac, ketamine, lidocaine, bupivacaine, flubiprofen) or hormone replacement 
(progesterone, estradiol, estriol, testosterone).  
A text-mining procedure was applied to 2013 data to reveal drug combinations that were frequently 
compounded together. Claims for compounded medications containing gabapentin (the most frequently 
compounded drug overall) tended to also contain baclofen (67.7%), cyclobenzaprine (64.1%), and ketamine 
(52.2%). Cyclobenzaprine (72.9%), gabapentin (61.4%), and baclofen (60.6%) were frequently presented in 
claims with flurbiprofen. Neither progesterone nor fluticasone was associated with other drugs in the same 
claim at or above the 50% confidence level. 
The most frequently compounded drugs for children and adolescents (< 20 years of age) were more diverse 
than those for adults (Table 3). The most commonly compounded medications for children were typically used 
for gastric acid suppression (omeprazole and lansoprazole), hypertension (enalapril, atenolol, spironolactone), 
and skin conditions (nystatin, hydrocortisone, zinc oxide, triamcinolone). The lists for 2012 (data not shown) 
and 2013 were substantially similar to each other. 
The ingredients that contributed the greatest cumulative costs to compounded medication claims in 2013 are 
shown in Table 4. Both active and inactive ingredients were included in this analysis, as the cost for 
compounded medications includes all ingredients. Gabapentin, ketamine, cyclobenzaprine, baclofen, lidocaine, 
flurbiprofen, and fluticasone were consistently among the most expensive ingredients for patients older than 10 
years in 2013. These drugs are commonly used individually and in various topical combinations for pain.24-27 
Custom Lipo-max Cream ® (Professional Compounding Centers of America (PCCA), Houston, TX), Lipoderm 
® (PCCA), and Pracasil Plus ® (PCCA), are proprietary non-medicated bases for topical drug products. Custom 
Lipo-Max® appeared in the lists for all groups aged 10 and over, and Lipoderm® appeared in the lists for all 
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groups aged 20 and over. There were several differences between the lists of most expensive ingredients for 
2012 (data not shown) and 2013 for patients over 10 years of age. Gabapentin, ketoprofen, ketamine, 
cyclobenzaprine, and baclofen appeared on some of the lists for 2012, but with lower frequency than in 2013. 
Similarly, the non-medicated topical bases appeared less frequently in 2012 than 2013. 
The highest-expense ingredients for patients under 10 years old in both 2012 (data not shown) and 2013 
primarily represented active drugs for treatment of a diverse array of medical conditions (influenza, gastric acid 
suppression, skin conditions). The inactive ingredients were Pracasil Plus® (2013), sodium bicarbonate (2013), 
and PCCA-Plus® oral syrup vehicle (2012 and 2013). 
Discussion 
The current study has established that compound users represented a small but increasing proportion of 
eligible members for the study period of 2012 – 2013. The rate of increase in prevalence of compound users 
(27.3%) and the number of claims for compounded medications (34.2%) were several times greater than the 
rate of increase in eligible members (1.9%). Utilization was consistent at approximately 2 compounded 
prescriptions PUPY. There was a concurrent increase of 130.3% in the mean ingredient cost for compounded 
medications. The total ingredient costs for compounded medications increased from $134 million in 2012 to 
$457 million in 2013. These finding are significant for managed care providers as they reconcile providing 
access to medications for members while containing costs for clients. The increases in utilization and costs of 
compounded medications may indicate a nascent trend that managed care providers should understand and 
plan for. 
Compounded prescriptions represented a similar percentage of users’ total prescription claims in both years 
of the study (6.9% in 2012, 6.8% in 2013). However, as a percentage of users’ total prescription cost, 
compounded medications increased by 76.2% from 2012 to 2103. The National Council for Prescription Drug 
Programs (NCPDP) implemented revised standards D.0 effective January 1, 2012.28 The coverage change 
incorporated inclusion of all ingredients in the compound medication for reimbursement as opposed to just the 
most expensive ingredient. Although the new standards went into effect January 1, 2012, pharmacy benefit 
managers had until April 1, 2012 to adopt and implement the standards. The pharmacy benefit manager 
providing data for this study adopted the standard starting January 1, 2012 but some claims that were 
inconsistent with D.0 were accepted until April 1, 2012. Implementation of the D.0 standards beginning in the 
second quarter of 2012 may have, in part, contributed to lower the ingredient costs for compounded 
medications in 2012.  
The decrease in median cost for compound users’ non-compounded prescriptions was surprising. Further 
investigation indicated that the primary cause was an increase in the generic fill rate for non-compounded 
prescriptions among these patients from 2012 to 2013 (data not shown). 
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There appear to be no other data in the peer-reviewed literature with which to compare the results of this 
analysis. Prior research on compounding by community pharmacists relied on pharmacists’ self-reports of their 
prescription dispensing volumes. The current data, on the other hand, represent a nationwide population and all 
of the claims submitted by eligible members for compounded medications for the two years studied. There are 
no comparable published data on compounded prescription costs. 
The prevalence of compound users was consistent across the US, as most states exhibited rates similar to the 
national average. Only four states had prevalence of compound users greater than 2% in 2013. Future research 
focused on states with high proportions of compound users may identify factors that predict compounded 
medication use and that contribute to the increasing number and costs of compounded prescriptions. 
Given the variety of drug therapy problems that compounding can address, diversity in the most frequently 
compounded drugs by age and gender was expected. Claims for patients under 10 years of age represented 
several therapeutic indications. However, the most frequently compounded drugs and most expensive 
ingredients were very similar across all adult age-gender groups. For example, 20 – 29 year old women and 60 
– 69 year old men had 9 of the 10 most frequently compounded drugs in common. The only drugs that were 
different between these groups were the hormone replacement products progesterone (women) and testosterone 
(men). The fact that pain management and hormone replacement were well-represented in the most frequently 
compounded drugs is not surprising, as pharmacists have previously reported these as significant niche areas for 
pharmacy compounding and two thirds of compound users were women.9, 13, 29 
Prior research indicated that pharmacists were frequently called upon by physicians to recommend specific 
compounded formulations appropriate to their patients’ medical needs.29, 30 Pharmacists may develop drug 
formulations based on their own research and experience, or they may obtain standardized formulations from 
medical and pharmacy journals, compounding suppliers, professional colleagues, etc. Standardization is 
generally beneficial, in that pharmacists who employ well-characterized formulations are more likely to 
compound medications of high quality, safety and purity.31 The high degree of association of several drugs in 
the same prescriptions suggests that a few standardized topical pain formulations were widely adopted. The 
sources of the formulations have not been rigorously investigated. However, there are several references that 
pharmacists may use to support their compounding practice. Every issue of the International Journal of 
Pharmaceutical Compounding (IJPC), for example, includes articles on professional and scientific issues 
related to compounding and specific example formulations for compounded medications. The formulations 
published in IJPC typically include quality control and stability information. The compounding supplier PCCA 
claims a “…database of more than 8,000 proprietary formulations that have been pre-tested…” and employs 
pharmacists to provide compounding-related technical support to their 3,600 member pharmacists in the US.32 
Thus, it is plausible that the homogeneity in most frequently prescribed drugs was due, at least in part, to a few 
11 
 
standardized topical pain formulations having been widely recommended by compounding pharmacists 
throughout the US. 
The average utilization of 2 compounded prescriptions PUPY was unexpectedly low, considering that the 
most frequently compounded drugs were typically recommended for medical issues with longer expected 
durations of therapy, such as chronic pain and hormone replacement.26, 33-40 The data suggest instead that most 
compounded medications were used for acute conditions. If so, the cost versus benefit relationship of the 
compounded medications would warrant further study, as there are numerous treatment modalities for acute 
pain syndromes, including manufactured drug products of several pharmacologic classes. It is also possible that 
the compounded medications were prescribed for chronic conditions, but the users discontinued them after a 
short duration of use due to unsatisfactory therapeutic response, loss of insurance coverage, etc. These data 
argue for research into patient satisfaction and adherence to therapy with compounded medications to elucidate 
the determinants of compounded medication use. 
Health plans and pharmacy benefit managers have responded to the increase in prevalence of compound 
users and costs of compounded medications by excluding ingredients used in compounding from 
reimbursement. Express Scripts announced in June 2014 that 1,000 ingredients used in compounding would no 
longer qualify for reimbursement beginning July 1, 2014.3 While the full list is confidential, a subset of 25 non-
covered ingredients was released to pharmacies. With the exceptions of lidocaine, testosterone, estradiol, estriol, 
progesterone, and triamcinolone acetonide, all of the 10 most frequently compounded drugs and 10 most 
expensive ingredients for adult age groups (≥ 20 years old) for 2013 appear on the excluded ingredient list 
(disclosed with permission). It is not clear if these exceptions will continue to be reimbursed. It is impossible to 
predict whether patients will continue to pay out of pocket for non-reimbursed compounded medications. 
However, the reimbursement of compounded medications for commercially insured patients is expected to 
decrease in 2014 due to the effects of the extensive ingredient exclusion lists. 
Limitations 
There were several limitations, many of which were derived from the exclusive use of pharmacy claims data. 
The study population consisted only of commercially insured patients. Workers’ compensation claims, 
Medicare claims, and non-insured prescriptions were not represented in the study. The study population was 
members who were eligible at any time throughout the 2 year study period, so claims from chronic compound 
users who were not continuously eligible may have decreased the PUPY utilization value. An unknown fraction 
of pharmacies do not accept pharmacy benefit cards for compounded medications.41 However, insured patients 
who purchased compounded medications from a non-participating pharmacy could submit a claim for 
reimbursement of the prescription, and these self-submitted claims were included in the database. 
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The study results are generalizable to retail pharmacy claims, as they constituted more than 99% of the 
compounded medication claims. Claims from hospitals, mail order, or other non-retail pharmacies constituted 
less than 1% of the compounded medication claims.  
Finally, the data did not include medical claims or diagnosis codes associated with conditions for which 
compounded medications were being prescribed. Inferences regarding the therapeutic indications for 
compounded medications were based on the drugs’ therapeutic classifications and users’ age and gender groups. 
Conclusions 
This is the first published study to profile trends in use of compounded medications using a diverse, 
nationwide pharmacy dataset. Compound users represented 1.4% of eligible members in 2013. The average 
ingredient cost for compound users’ compounded prescriptions ($710.36) was greater than for non-compounded 
prescriptions ($160.20). The one-year increase in average compounded prescription costs (130.3%) was also 
greater than for non-compounded prescriptions (7.7%). Although prevalence of compound users and the PUPY 
utilization of compounded prescriptions increased only slightly between 2012 and 2013, the mean and median 
cost of compounded medications increased dramatically during this time. Text mining revealed that drug 
combinations characteristic of topical pain formulations were among the most frequently compounded 
medications for adults. 
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Table 1. Demographic data 
 
 2012 2013 Change 
Eligible members 22,314,101 22,745,508 431,407 (1.9%) 
Prescription medication users 14,960,649 15,110,518 149,869 (1.0%) 
Prevalence of prescription medication users 
Average age (standard deviation) 
Female 
Percent female  
67.0% 
36.9 (20.7) 
11,508,347 
51.6% 
66.4% 
36.8 (20.6) 
11,713,474 
51.5% 
–0.9% 
–0.1 yr 
1.8% 
–0.2% 
              Compound users 245,285 323,501 78,216 (31.9%) 
Prevalence of compound users 
Average age (standard deviation) 
Female 
Percent female  
1.1% 
41.8 (21.3) 
162,471 
66.2% 
1.4% 
42.3 (21.1) 
212,590 
65.7% 
27.3% 
0.5 yr 
30.8% 
–0.8% 
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Table 2. Medication costs and utilization among compound users, 2012 – 2013. 
 
 2012 2013 Change 
All prescriptions  7,083,961 9,677,954 36.6% 
Ingredient cost                        Mean 
Median 
Standard deviation 
$163.42 
32.57 
1,340.64 
$209.76 
27.86 
38,715.93 
28.4% 
–14.5% 
                 Compounded prescriptions 486,886 653,360 34.2% 
Ingredient cost                       Mean 
Median 
Standard deviation 
PUPY utilization 
                                       Compounded prescriptions as percent 
of prescription claims 
                                   Compounded prescriptions as percent 
of ingredient cost 
$308.49 
61.00 
1,220.27 
1.98 
6.9% 
 
13.0% 
$710.36 
94.49 
3,076.07 
2.02 
6.8% 
 
22.9% 
130.3% 
54.9% 
 
2.0% 
–1.8% 
 
76.2% 
                  Non-compounded prescriptions 6,597,075 9,024,593 36.8% 
Ingredient cost                       Mean 
Median 
Standard deviation 
$148.75 
29.63 
1,351.35 
$160.20 
24.39 
40,575.40 
7.7% 
–17.7% 
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Table 3. Ten most frequently compounded drugs by user age and gender, 2013 
 < 10 10 – 19 20 – 29 30 – 39 40 – 49 50 – 59 60 – 69 ≥ 70 
Rank  F M F M F M F M F M F M F M F M 
1 Omepra
zole 
Omepra
zole 
Baclofe
n 
Baclofe
n 
Baclofe
n 
Baclofe
n 
Gabape
ntin 
Gabape
ntin 
Progest
erone 
Baclofe
n 
Progest
erone 
Gabape
ntin 
Progest
erone 
Gabape
ntin 
Gabape
ntin 
Gabape
ntin 
2 Lansopr
azole 
Lansopr
azole 
Cyclobe
nzaprin
e HCl 
Cyclobe
nzaprin
e HCl 
Gabape
ntin 
Cyclobe
nzaprin
e HCl 
Progest
erone 
Baclofe
n 
Gabape
ntin 
Gabape
ntin 
Estradio
l 
Baclofe
n 
Estradio
l 
Baclofe
n 
Baclofe
n 
Baclofe
n 
3 Enalapri
l 
maleate 
Enalapri
l 
maleate 
Gabape
ntin 
Lidocai
ne HCl 
viscous 
Cyclobe
nzaprin
e HCl 
Gabape
ntin 
Baclofe
n 
Cyclobe
nzaprin
e HCl 
Baclofe
n 
Cyclobe
nzaprin
e HCl 
Testoste
rone 
Cyclobe
nzaprin
e HCl 
Gabape
ntin 
Cyclobe
nzaprin
e HCl 
Cyclobe
nzaprin
e HCl 
Cyclobe
nzaprin
e HCl 
4 Nystatin Oseltam
ivir 
Lidocai
ne HCl 
viscous 
Methylc
obalami
n 
Ketami
ne HCl 
Ketami
ne HCl 
Cyclobe
nzaprin
e HCl 
Ketami
ne HCl 
Cyclobe
nzaprin
e HCl 
Ketami
ne HCl 
Gabape
ntin 
Testoste
rone 
Baclofe
n 
Testoste
rone 
Diclofe
nac 
sodium 
Diclofe
nac 
sodium 
5 Oseltam
ivir 
Hydroc
ortisone 
Diclofe
nac 
sodium 
Salicyli
c acid 
Diclofe
nac 
sodium 
Diclofe
nac 
sodium 
Ketami
ne HCl 
Diclofe
nac 
sodium 
Testoste
rone 
Diclofe
nac 
sodium 
Baclofe
n 
Ketami
ne HCl 
Testoste
rone 
Ketami
ne HCl 
Ketami
ne HCl 
Ketami
ne HCl 
6 Hydroc
ortisone 
Nystatin Salicyli
c acid 
Gabape
ntin 
Progest
erone 
Lidocai
ne 
Diclofe
nac 
sodium 
Lidocai
ne 
Estradio
l 
Testoste
rone 
Cyclobe
nzaprin
e HCl 
Diclofe
nac 
sodium 
Cyclobe
nzaprin
e HCl 
Diclofe
nac 
sodium 
Lidocai
ne 
Testoste
rone 
7 Zinc 
oxide 
Zinc 
oxide 
Lidocai
ne 
Diclofe
nac 
sodium 
Lidocai
ne 
Lidocai
ne HCl 
viscous 
Lidocai
ne 
Bupivac
aine 
HCl 
Ketami
ne HCl 
Lidocai
ne 
Estriol Lidocai
ne 
Diclofe
nac 
sodium 
Lidocai
ne 
Bupivac
aine 
HCl 
Lidocai
ne 
8 Ursodio
l 
Baclofe
n 
Hydroc
ortisone 
Omepra
zole 
Bupivac
aine 
HCl 
Flurbipr
ofen 
Bupivac
aine 
HCl 
Flurbipr
ofen 
Diclofe
nac 
sodium 
Bupivac
aine 
HCl 
Diclofe
nac 
sodium 
Bupivac
aine 
HCl 
Ketami
ne HCl 
Bupivac
aine 
HCl 
Progest
erone 
Bupivac
aine 
HCl 
9 Atenolo
l 
Spirono
lactone 
Ketami
ne HCl 
Lidocai
ne 
Flurbipr
ofen 
Bupivac
aine 
HCl 
Flurbipr
ofen 
Lidocai
ne HCL 
Lidocai
ne 
Flurbipr
ofen 
Ketami
ne HCl 
Flurbipr
ofen 
Estriol Flurbipr
ofen 
Lidocai
ne HCL 
Lidocai
ne HCL 
10 Baclofe
n 
Triamci
nolone 
acetonid
e 
Bupivac
aine 
HCl 
Ketami
ne HCl 
Lidocai
ne HCL 
Lidocai
ne HCL 
Testoste
rone 
Testoste
rone 
Bupivac
aine 
HCl 
Lidocai
ne HCL 
Lidocai
ne 
Lidocai
ne HCL 
Lidocai
ne 
Lidocai
ne HCL 
Estradio
l 
Triamci
nolone 
acetonid
e 
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Table 4. Ten most expensive ingredients in compounded medications by user age and gender, 2013. 
 < 10 10 – 19 20 – 29 30 – 39 40 – 49 50 – 59 60 – 69 ≥ 70 
Rank  F M F M F M F M F M F M F M F M 
1 Oseltami
vir 
Oseltami
vir 
Gabapent
in 
Gabapent
in 
Gabapent
in 
Gabapent
in 
Gabapent
in 
Gabapent
in 
Gabapent
in 
Gabapent
in 
Gabapent
in 
Gabapent
in 
Gabapent
in 
Gabapent
in 
Gabapent
in 
Gabapent
in 
2 Lansopra
zole 
Omepraz
ole 
Fluticaso
ne 
propriona
te 
Fluticaso
ne 
propriona
te 
Fluticaso
ne 
propriona
te 
Ketamine 
HCl 
Ketamine 
HCl 
Ketamine 
HCl 
Ketamine 
HCl 
Ketamine 
HCl 
Ketamine 
HCl 
Ketamine 
HCl 
Ketamine 
HCl 
Ketamine 
HCl 
Ketamine 
HCl 
Ketamine 
HCl 
3 Fluticaso
ne 
propriona
te 
Lansopra
zole 
Flurbipro
fen 
Flurbipro
fen 
Ketamine 
HCl 
Flurbipro
fen 
Fluticaso
ne 
propriona
te 
Flurbipro
fen 
Flurbipro
fen 
Flurbipro
fen 
Flurbipro
fen 
Flurbipro
fen 
Flurbipro
fen 
Flurbipro
fen 
Flurbipro
fen 
Flurbipro
fen 
4 Omepraz
ole 
Methylco
balamin 
Ketamine 
HCl 
Ubiquino
l 
Flurbipro
fen 
Fluticaso
ne 
propriona
te 
Flurbipro
fen 
Fluticaso
ne 
propriona
te 
Fluticaso
ne 
propriona
te 
Custom 
Lipo-
max (TM) 
Custom 
Lipo-
max (TM) 
Custom 
Lipo-
max (TM) 
Custom 
Lipo-
max (TM) 
Custom 
Lipo-
max (TM) 
Custom 
Lipo-
max (TM) 
Custom 
Lipo-
max (TM) 
5 Sildenafil Leucovor
in 
calcium 
Custom 
Lipo-
max (TM) 
Ketamine 
HCl 
Custom 
Lipo-
max (TM) 
Custom 
Lipo-
max (TM) 
Custom 
Lipo-
max (TM) 
Testoster
one 
Custom 
Lipo-
max (TM) 
Cycloben
zaprine 
HCl 
Cycloben
zaprine 
HCl 
Cycloben
zaprine 
HCl 
Cycloben
zaprine 
HCl 
Cycloben
zaprine 
HCl 
Cycloben
zaprine 
HCl 
Cycloben
zaprine 
HCl 
6 Tacrolim
us 
Sildenafil Cycloben
zaprine 
HCl 
Custom 
Lipo-
max (TM) 
Pracasil(T
M)
 Plus 
Cycloben
zaprine 
HCl 
Cycloben
zaprine 
HCl 
Cycloben
zaprine 
HCl 
Cycloben
zaprine 
HCl 
Fluticaso
ne 
propriona
te 
Fluticaso
ne 
propriona
te 
Baclofen Baclofen Baclofen Baclofen Baclofen 
7 Nystatin Ubiquino
l 
Pracasil(T
M)
 Plus 
Cycloben
zaprine 
HCl 
Cycloben
zaprine 
HCl 
Baclofen Pracasil(T
M)
 Plus 
Custom 
Lipo-
max (TM) 
Baclofen Baclofen Baclofen Testoster
one 
Fluticaso
ne 
propriona
te 
Alprosta
dil 
Lipoder
m (TM) 
base 
Lipoder
m (TM) 
base 
8 Pracasil(T
M)
 Plus 
Sodium 
bicarbon
ate 
Baclofen Oseltami
vir 
Baclofen Lipoder
m 
(TM)base 
Baclofen Baclofen Lipoder
m (TM) 
base 
Testoster
one 
Lipoder
m (TM) 
base 
Lipoder
m (TM) 
base 
Lipoder
m (TM) 
base 
Lipoder
m (TM) 
base 
Ketoprof
en 
Ketoprof
en 
9 Baclofen Tacrolim
us 
Lipderm 
(TM)
 base 
Pracasil(T
M)
 Plus 
Mometas
one 
furoate 
Pracasil(T
M)
 Plus 
Lipoder
m (TM) 
base 
Lipoder
m 
(TM)base 
Pracasil(T
M)
 Plus 
Lipoder
m (TM) 
base 
Progester
one 
Fluticaso
ne 
propriona
te 
Progester
one 
Testoster
one 
Diclofen
ac 
sodium 
Testoster
one 
10 Sodium 
bicarbon
ate 
PCCA-
Plus(TM) 
Oseltami
vir 
Baclofen Lipoder
m (TM) 
base 
Mometas
one 
furoate 
Bupivaca
ine HCl 
Ethoxy 
diglycol 
Progester
one 
Ethoxy 
diglycol 
Diclofen
ac 
sodium 
Bupivaca
ine HCl 
Mometas
one 
furoate 
Fluticaso
ne 
propriona
te 
Bupivaca
ine HCl 
Diclofen
ac 
sodium 
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 Figure 1. Age and gender distribution of compound users. 
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Figure 2. Prevalence of compound users by state of residence for 2013 and change in prevalence 
of compound users 2012 to 2013. 
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Figure 3. Ingredient cost distribution for compound users’ prescription claims.  
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